Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Septerna, Inc. (NASDAQ:SEPN) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $26.75.

SEPN has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of Septerna in a research report on Friday, September 5th. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Septerna in a research report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Saturday, September 27th. Finally, Wall Street Zen upgraded Septerna from a “sell” rating to a “hold” rating in a research report on Sunday, September 21st.

Septerna Stock Up 2.6%

Shares of Septerna stock opened at $20.68 on Friday. The stock’s 50-day simple moving average is $13.89 and its 200-day simple moving average is $10.55. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The company has a market capitalization of $921.91 million and a price-to-earnings ratio of -2.05.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $22.50 million. On average, equities analysts expect that Septerna will post -7.11 earnings per share for the current year.

Institutional Investors Weigh In On Septerna

Hedge funds have recently made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of Septerna in the first quarter worth about $139,000. Checkpoint Capital L.P. purchased a new stake in shares of Septerna in the first quarter worth about $4,776,000. ADAR1 Capital Management LLC purchased a new stake in shares of Septerna in the first quarter worth about $4,174,000. Swiss National Bank purchased a new stake in shares of Septerna in the first quarter worth about $174,000. Finally, Stoneridge Investment Partners LLC purchased a new stake in shares of Septerna in the first quarter worth about $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.